| DB ID | MyCo_3000 |
| Title | Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection |
| Year | 2014 |
| PMID | 25002471 |
| Fungal Diseases involved | Invasive fungal infection |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | All animal experiments were approved by the University of Texas MD Anderson Cancer Center Institutional Animal Care and Use Committee. Eight-week-old female NSG mice (Jackson Laboratory) weighing 18–20 g were used and housed in a sterile facility. |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Peripheral blood samples |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | Lck |
| Biomarker Full Name | Lymphocyte-specific protein tyrosine kinase |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | USA |
| Cohort | None |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | 3 |
| Pathway | None |
| Disease Introduction Mechanism | Opportunistic invasive fungal infections (IFI) by Aspergillus spp. cause morbidity and mortality in immunocompromised patients. Mortality rates associated with invasive Aspergillus (IA) are 22% in patients receiving solid-organ transplants and 60–85% in patients receiving hematopoietic stem cell transplants (HSCT). Antifungal agents such as polyenes, triazoles, and echinocandins can be rendered ineffective by suboptimal host immunity, emergence of drug-resistant strains, and attendant toxicities in the recipients. Thus, new approaches for treating IAs are needed. Because the adoptive transfer of genetically modified T cells expressing CD19-specific chimeric antigen receptors (CARs) has resulted in successful treatment of patients with B-cell malignancies, we sought to determine if a CAR could be developed to redirect T-cell specificity to Aspergillus. |
| Technique | Immunological assay |
| Analysis Method | FDA Approved Bioengineering T cells Approach (nonviral Sleeping Beauty gene-transfer system) |
| ELISA kits | None |
| Assay Data | Bioengineering T cells Approach (nonviral Sleeping Beauty gene-transfer system) |
| Validation Techniques used | qPCR, FDA Approved Bioengineering T cells Approach (nonviral Sleeping Beauty gene-transfer system) |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
